Congress Materials - Genitourinary Cancers Symposium (GU 2024)
2024 Genitourinary Cancers Symposium | Jan 25-27 | San Francisco, CA
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Analysis of Real-World Survival for Patients with Metastatic Castration-Sensitive Prostate Cancer Treated with Apalutamide or Abiraterone Acetate in an Oncology Database: ROMA Study
Mehmet A. Bilen, Ibrahim Khilfeh, Carmine Rossi, Shawn Du, Jill Korsiak, Alvi Rahman, Patrick Lefebvre, Dominic Pilon, Neal D. Shore
Apalutamide Plus Intermittent Versus Continuous Androgen Deprivation Therapy in Participants With Metastatic Hormone-Sensitive Prostate Cancer: LIBERTAS Phase 3 Study Design
Arun Azad, Marco Antonio Badillo, Qiang Dong, Alicia K. Morgans, Dana E. Rathkopf, Karie Runcie, Tian Zhang, Raj S. Pruthi, Amitabha Bhaumik, Suneel D. Mundle, Sharon A. McCarthy, Angela Lopez-Gitlitz, Jennifer Whalen, Ashita S. Batavia, Clark Musto, Shir Netanel, Daniel P. Sanchez, Neeraj Agarwal
Baseline Characteristics of PSMA-PET Positive and Negative Patients With High-risk Biochemical Recurrence (BCR) After Radical Prostatectomy (RP) in the Ongoing Phase 3 PRIMORDIUM Study
Boris A. Hadaschik, Nicolas Mottet, Piet Ost, Cosimo De Nunzio, Nina Tunariu, Renata Zaucha, Klaus Brasso, Ignacio Osman-Garcia, Deniz Tural, Martin Lukac, Hind Stitou, Geneviève Pissart, Michela Efficace, Stefano Fanti
Estimating Median Overall Survival of Apalutamide Compared with Placebo in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Populations: Statistical Extrapolations of the TITAN Study
Neeraj Agarwal, Anders Bjartell, Álvaro Juárez, Ronja Kerßenboom, Nolen Perualila, Peter Wigfield, Kim N. Chi
Impact of a Rash Management Guide on Incidence and Severity of Rash with Apalutamide: Experience from the Apa-RP Study in High-risk Localized Prostate Cancer
Neal Shore, Jason Hafron, Daniel Saltzstein, Amitabha Bhaumik, Pankaj Aggarwal, Rushikesh Potdar, Jennifer Phillips, Tracy McGowan
Influential Factors Impacting Treatment Decision-Making and Decision Regret in Patients With Localized or Locally Advanced Prostate Cancer
Benjamin A. Gartrell, Angaja Phalguni, Paulina Bajko, Suneel D. Mundle, Sharon A. McCarthy, Sabine D. Brookman-May, Francesco De Solda, Ruhee Jain, Wellam Yu Ko, Guillaume Ploussard, Boris Hadaschik
Patient-Reported Outcomes (PRO) in Patients (Pts) with BRCA1/2-Altered Metastatic Castration-Resistant Prostate Cancer (mCRPC) Receiving Niraparib (NIRA) with Abiraterone Acetate and Prednisone (AAP): Results from Final Analysis of the MAGNITUDE Study
Dana E. Rathkopf, Guilhem Roubaud, Kim N. Chi, Eleni Efstathiou, Gerhardt Attard, David Olmos, Eric J. Small, Marniza Saad, Elena Castro, Won Kim, Daphne Wu, Kristi Bertzos, Shiva Dibaj, Jenny Zhang, Peter Francis, Matthew R. Smith
Population Based Trends in Intravesical Gemcitabine Use Among Patients With High-Risk Non-Muscle-Invasive Bladder Cancer
Stephen B. Williams, Jinghua He, Aeja Jackson, Andrea Ireland, Hiremagalur Balaji, Wenxi Huang, Qian Shi, Lorie Ellis, Mukul Singhal
Preclinical Characterization of Human Kallikrein 2 (hK2) as a Novel Target for the Treatment of Prostate Cancer
Fei Shen, William Kevin Kelly, Neeta Pandit-Taskar, Theresa McDevitt, Ryan Smith, Krista Menard, Kathryn Packman, Ruchi Chaudhary, Brent Rupnow, Margaret Yu, Mary Guckert, Ken Tian, Gerald Chu, Hong Xie, Daniel Patricia, Steven Max, Michael J. Morris
Prostate-Specific Antigen Response Among Patients with Metastatic Castration-Sensitive Prostate Cancer Initiated on Apalutamide or Abiraterone Acetate in Real-World Urology Practices (PROMPT-2)
Gordon Brown, Ibrahim Khilfeh, Shawn Du, Carmine Rossi, Lilian Diaz, Frederic Kinkead, Erik Muser, Jill Korsiak, Patrick Lefebvre, Dominic Pilon, Lorie Ellis, Benjamin H. Lowentritt
Real-World Comparison of Prostate-Specific Antigen Response in Patients with Metastatic Castration-Sensitive Prostate Cancer Treated with Apalutamide or Enzalutamide (PROMPT-1)
Benjamin H. Lowentritt, Shawn Du, Dominic Pilon, Ibrahim Khilfeh, Erik Muser, Carmine Rossi, Frederic Kinkead, Lilian Diaz, Jill Korsiak, Lorie Ellis, Patrick Lefebvre, Gordon Brown
Real-world Economic Burden of Patients With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Deborah R. Kaye, Ibrahim Khilfeh, Erik Muser, Laura Morrison, Ana Urosevic, Frederic Kinkead, Patrick Lefebvre, Dominic Pilon, Daniel J. George
Real World Experience of FGFR Gene Alterations and Clinical Outcomes in Advanced/ Metastatic Urothelial Cancer in Japan: MONSTAR-SCREEN Database Study —UroCaMon—
Nobuaki Matsubara, Takahiro Osawa, Takashige Abe, Mototsugu Oya, Koshiro Nishimoto, Toshiyuki Iwahori, Hiroaki Tsuchiya, Maiko Murota, Masaki Yoshida, Yohei Tatematsu, Yosuke Nakano, Masatoshi Eto, Norio Nonomura
Real-World Survival of Patients with Metastatic Castration-Sensitive Prostate Cancer Initiated on Apalutamide or Enzalutamide in an Oncology Database: ROME Study
Mehmet A. Bilen, Shawn Du, Ibrahim Khilfeh, Carmine Rossi, Jill Korsiak, Alvi Rahman, Patrick Lefebvre, Dominic Pilon, Neal D. Shore
Real-World Treatment Patterns in Patients with BRCA1/2-Positive Metastatic Castration-Resistant Prostate Cancer Initiating First-Line Therapy
Mehmet A. Bilen, Ibrahim Khilfeh, Kevin H. Li, Carmine Rossi, Erik Muser, Laura Morrison, Annalise Hilts, Lilian Diaz, Patrick Lefebvre, Dominic Pilon, Daniel J. George
Reasons for Refusal of or Ineligibility for Radical Cystectomy in Patients With Bacillus Calmette–Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer From the SunRISe-1 Study
Joseph M. Jacob, Felix Guerrero-Ramos, Evanguelos Xylinas, Giuseppe Simone, Yair Lotan, Christopher Pieczonka, Harm Arentsen, Andrea Necchi, Girish Kulkarni, Manish I. Patel, David Cahn, Jong Kil Nam, Martin Bögemann, Shalaka Hampras, Katherine Stromberg, Jason Martin, Abhijit Shukla, Hussein Sweiti, Michiel van der Heijden
Survival Outcomes of APA as a Starting treatment: Impact in real-world patients with mCSPC (OASIS)
Benjamin L. Maughan, Yanfang Liu, Suneel Mundle, Mehregan Nematian-Samani, Xiayi Wang, Shawn Du, Lawrence Karsh
Urine-Based Testing for Patient Selection and Genomic Characterization of Patients With FGFR Alteration-Positive Non-Muscle-Invasive Bladder Cancer Treated With TAR-210
Roger Li, Ja Hyeon Ku, Antoni Vilaseca Cabo, Felix Guerrero-Ramos, Joshua Meeks, Neil Beeharry, Michelle Quiroz, Jiarui Zhang, Denis Smirnov, Yashoda Rajpurohit, Bethany Brunton, Gabriela Martinez, Carrye Cost, Anna Kalota, Josh Lauring, Nicole L. Stone, Shibu Thomas
Copies of these presentations are for personal use only and may not be reproduced without permission from ASCO® or the author of this presentation.